Adverse events in patients re-exposed to bone morphogenetic protein for spine surgery

Spine

Volumn 33, Issue 4, 2008, Pages 391-393

  Carreon, Leah Y ^a   Glassman, Steven D ^a,b   Brock, Dylan C ^c   Dimar, John R ^a,b   Puno, Rolando M ^a,b   Campbell, Mitchell J ^a,b  

^a NORTON LEATHERMAN SPINE CENTER   (United States)

^b University of Louisville School of Medicine   (United States)

^c NEW YORK UNIVERSITY   (United States)

Author keywords

Bone morphogenetic protein 2; Complications; Lumbar spine fusion; Morbidity

Indexed keywords

RECOMBINANT BONE MORPHOGENETIC PROTEIN 2;

ARTICLE; BONE GRAFT; CONTROLLED STUDY; DEBRIDEMENT; DEMOGRAPHY; FEMALE; HUMAN; INFLAMMATION; INJURY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRIORITY JOURNAL; SPINE FUSION; SPINE SURGERY; WOUND;

BONE MORPHOGENETIC PROTEINS; BONE SUBSTITUTES; FEMALE; HUMANS; LOGISTIC MODELS; MALE; RECOMBINANT PROTEINS; REOPERATION; SPINAL DISEASES; SPINAL FUSION; SURGICAL WOUND INFECTION; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME;

EID: 39649098243     PISSN: 03622436     EISSN: 15281159     Source Type: Journal    
DOI: 10.1097/BRS.0b013e3181642a49     Document Type: Article

References (24)

1. Baskin DS, Ryan P, Sonntag V, et al. A prospective, randomized, controlled cervical fusion study using recombinant human bone morphogenetic protein-2 with the cornerstone-SR allograph ring and the Atlantis anterior cervical plate. Spine 2003;28:1219-25.
2. Burkus JK, Heim SE, Gornet MF, et al. Is INFUSE bone graft superior to autograft bone? An integrated analysis of clinical trials using the LT-CAGE lumbar tapered fusion device. J Spinal Disord Tech 2003;16:113-22.
3. Dimar JR, Glassman SD, Burkus KJ, et al. Clinical outcomes and fusion success at 2 years of single-level instrumented posterolateral fusions with recombinant human bone morphogenetic protein-2/compression resistant matrix versus iliac crest bone graft. Spine 2006 15;31:2534-9; discussion 2540.
4. Glassman SD, Dimar JR, Carreon LY, et al. Initial fusion rates with rh-BMP-2 and HA-TCP/collagen carrier in posterolateral fusion. Spine 2005;30:1694-8.
5. Shields LB, Raque GH, Glassman SD, et al. Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion. Spine 2006;31:542-7.
6. Smucker JD, Rhee JM, Singh k, et al. Increased swelling complications associated with off-label usage of rhBMP-2 in the anterior cervical spine. Spine 2006;31:2813-19.
7. Hansen SM, Sasso RC. Resorptive response of rhBMP2 simulating infection in an anterior lumbar interbody fusion with a femoral ring. J Spinal Disord Tech 2006;19:130-4.
8. McClellan JW, Mulconrey DS, Forbes RJ, et al. Vertebral bone resorption after transforaminal lumbar interbody fusion with bone morphogenetic protein (rhBMP-2). J Spinal Disord Tech 2006;19:483-6.
9. Pradhan BB, Bae HW, Dawson EG, et al. Graft resorption with the use of bone morphogenetic protein: lessons from anterior lumbar interbody fusion using femoral ring allografts and recombinant human bone morphogenetic protein-2. Spine 2006;31:E277-E284.
10. Carreon LY, Puno RM, Dimar JR, et al. Perioperative complications of posterior lumbar decompression and arthrodesis in older adults. J Bone Joint Surg 2003;85A:2089-92.
11. Cassinellli EH, Eubanks J, Vogt M, et al. Risk factors for the development of perioperative complications in elderly patients undergoing lumbar decompression and arthrodesis for spinal stenosis. an analysis of 166 patients. Spine 2007;32:230-5.
12. Glassman SD, Alegre G, Carreon LY, et al. Perioperative complications of lumbar instrumentation and fusion in patients with diabetes mellitus. Spine J 2003;3:496-501.
13. McDonnell MF, Glassman SD, Dimar JR II, et al. Perioperative complications of anterior procedures on the spine. J Bone Joint Surg 1996;78:839-47.
14. Raffo CS, Lauerman WC. Predicting morbidity and mortality of lumbar spine arthrodesis in patients in their ninth decade. Spine 2006;31:99-103.
15. Zheng F, Cammisa FP, Sandhu HS, et al. Factors predicting hospital stay, operative time, blood loss and transfusion in patients undergoing revision posterior lumbar spine decompression, fusion and segmental instrumentation. Spine 2002;27:818-24.
16. Boyne PJ, Marx RE, Nevins M, et al. A feasibility study evaluating rhBMP-2/absorbable collagen sponge for maxillary sinus floor augmentation. Int J Periodontics Restorative Dent 1997;17:11-25.
17. Lind M, Eriksen EF, Bunger C. Bone morphogenetic protein-2 but not bone morphogenetic protein-4 and -6 stimulates chemotactic migration of human osteoblasts, human marrow osteoblasts and U2-OS cells. Bone 1996;18:53-7.
18. McKay WF, Peckham SM, Marotta JS. The Science of rhBMP-2. St. Louis, MO: Quality Medical Publishing, Inc; 2006:27-8.
19. Wozney JM. Bone morphogenetic proteins and their gene expression. In: Noda M, ed. Molecular and Cellular Biology of Bone. San Diego: Academic Press; 1993:131-67.
20. Boakye M, Mummaneni PV, Garrett M, et al. Anterior cervical discectomy and fusion involving a polytheretherketone spacer and bone morphogenetic protein. J Neurosurg 2005;2:521-5.
21. Boden SD, Kang J, Sandhu H, et al. Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies. Spine 2002;27:2662-73.
22. Kleeman TJ, Michael Ahn U, Clutterbuck WB, et al. Laparoscopic anterior lumbar interbody fusion at L4-L5: an anatomic evaluation and approach classification. Spine 2002;27:1390-5.
23. Lanman TH, Hopkins TJ. Early findings in a pilot study of anterior cervical interbody fusion in which recombinant human bone morphogenetic protein-2 was used with poly(lactide-co-D,L-lactide) bioabsorbable implants. Neurosurg Focus 2004;16:E6.
24. Poynton AR, Lane JM. Safety profile for the clinical use of bone morphogenetic proteins in the spine. Spine 2002;27(16S):S40-S48.